$0.83
+0.03 (+3.24%)
Open$0.82
Previous Close$0.81
Day High$0.88
Day Low$0.81
52W High$1.85
52W Low$0.45
Volume—
Avg Volume253.2K
Market Cap145.25M
P/E Ratio—
EPS$-0.37
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,329.3% upside
Current
$0.83
$0.83
Target
$20.19
$20.19
$14.44
$20.19 avg
$28.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 14.90M | 15.53M | 15.53M |
| Net Income | 2.54M | 3.35M | 2.88M |
| Profit Margin | 17.0% | 21.6% | 18.5% |
| EBITDA | 5.18M | 5.39M | 5.26M |
| Free Cash Flow | 2.62M | 3.23M | 2.70M |
| Rev Growth | -8.5% | -1.6% | +3.5% |
| Debt/Equity | 0.17 | 0.17 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |